Historically, adjuvant androgen deprivation therapy has been viewed as a palliative treatment option for patients with poor-prognosis non-metastatic prostate cancer. In addition, guidelines from bodies such as the European Association of Urology and American Society for Clinical Oncology do not specifically categorize adjuvant hormonal therapy as being curative in intent. We propose that adjuvant androgen deprivation therapy should now be classified as a treatment of curative intent in patients with poor-prognosis, non-metastatic prostate cancer. By applying a carefully considered definition of cure (based on long-term (10-to 15-year) disease-free survival curves) to the findings from randomized controlled clinical trials that have studied adjuvant hormonal treatments in nonmetastatic prostate cancer, we challenged whether this viewpoint should now be considered redundant. According to our review of relevant studies and our definition of cure, goserelin appears to augment cure in a sizeable proportion of men with poor-prognosis non-metastatic prostate cancer when given adjuvant to radical prostatectomy or radiotherapy. Across several trials, the relevant survival curves for the goserelin-treated population became indefinitely flat after long-term followup. This indicates that these patients have a mortality risk comparable to the general population without prostate cancer. On the basis of the evidence presented within this review, we believe that, given it can control disease for a long period of time, adjuvant goserelin should be reclassified as a treatment of curative intent for patients with poor-prognosis non-metastatic prostate cancer.
Introduction
Physicians managing patients with cancer seek to permanently rid their patients of the disease. However, current technology makes it difficult to determine whether a patient is entirely free of cancer. Although physical signs of the tumor, including imaging tests and biological markers, may be negative, it is usually impossible to determine if all remnants of the disease have been eradicated. Because of these uncertainties, oncologists are very reluctant to use the term 'cure'. As the understanding of cancer biology continues to evolve, it is increasingly evident that the concept of cure is somewhat naïve. Patients may live with existing cancer cells for decades and increasingly sensitive markers are identifying residual or recurrent disease many years prior to clinical manifestation. Many patients with treated, but not cured cancers, die of other diseases, rendering the concept even more confusing. This may lead to a situation where long-term control of disease is of clinical importance.
In the 1970s, Frei and Gehan 1 outlined a definition of cure in the setting of cancer, which proposed that cure exists among a group of disease-free survivors whose progressive death rate from all causes is similar to that of an age-and sex-matched population. This concept first led to 5-year survival rates becoming widely accepted as an indication of the success of a cancer treatment. However, over the past 30 years, earlier detection, improved therapies and better data acquisition have made the 5-year survival concept obsolete for many cancers. This is particularly evident with relatively slowgrowing tumors such as prostate cancer, when life may not be threatened by the disease for 10-20 years. 2 In these cases, a longer-term view is required to establish whether treatment results in adequate long-term control, leading to cure of the disease.
In contrast to physicians, many patients with cancer have high expectations of treatment and are desirous to know whether a given treatment will offer them cure. 3 Although 'cure' may be too definitive a word to use in discussions with patients, it is nonetheless referred to in the lay literature and in patient/patient and patient/ family discussions. 4 For certain stages of some cancers including genitourinary cancers, cure is becoming a reality. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although general opinion is that patients with poor-prognosis nonmetastatic prostate cancer cannot be cured, results from recent studies have prompted re-evaluation of this belief. The aim of this review is to examine the concept of cure in genitourinary cancers and focus on the role of adjuvant hormonal therapy in prostate cancer, with reference to re-examining the historical treatment paradigm, which considers androgen deprivation a palliative option.
Is cure possible for patients with poor-prognosis non-metastatic prostate cancer?
Defining cure in prostate cancer
Several hypothetical examples of Kaplan-Meier curves of 10-year duration are shown in Figure 1 . The lifeexpectancy curve of the general population is shown in Figure 1a and, as anticipated, this curve remains generally flat. Figure 1b shows two patient populations not being cured by treatment: these overall disease-free survival curves progressively decrease over the longterm and never become parallel to the normal lifeexpectancy curve, indicating individuals are continuing to relapse. However, the population in Figure 1b with the higher median disease-free survival (treatment 1) would have remained cancer free for longer. In contrast with this example, Figure 1c shows a population where a proportion of patients are being cured by treatment: the disease-free survival curve of the treated population flattens out indefinitely as it approaches 10 years of follow-up, thus mirroring the survival curve seen in the general population. The curve associated with the control population in Figure 1c also flattens indefinitely, over an extended period of time, albeit after most patients have relapsed. When the control population flattens, we believe that only a negligible proportion of disease-free patients will subsequently experience relapse. Consequently, from this time point onward, it is our opinion that disease-free patients can be considered cured. By a curve flattening we do not mean to say that all patients are necessarily cured, but that the slope of the curve is not statistically different from zero, or that some patients who were otherwise destined to die from their disease do not as a result of prolonged cancer control. An additional important concept in the cure of cancer is that the treatment used to achieve cure should not cause Treatment of poor prognosis, nonmetastatic prostate cancer N Fleshner et al significant death due to toxicity. Diethylstilbestrol, given at high doses in the Veteran's Administration Cooperative Urological Research Group Study 1, is a classic example of this phenomenon, where disease-free survival was improved but overall survival was not, due to iatrogenic. 21 On the basis of these observations, and the natural history of the disease course for prostate cancer, we propose an amended definition for cure specific to prostate cancer. Treatment of prostate cancer can be considered curative and cancer control achieved when: (a) the disease-free survival curve associated with the treated patient population flattens after 1015 years and (b) non-cancer-related deaths in the treated patient population are not significantly different from those in the general population. In the case of randomized controlled trials, the disease-free survival became parallel to the curve of the general population. This means that a proportion of patients surviving at 10-15 years have a risk of mortality similar to the general population without prostate cancer. This definition of cure through long-term control of disease will be applied throughout the remainder of this review.
Challenging the historical paradigm of androgen deprivation therapy as palliative
Radical therapies are generally recognized to be potentially curative options for patients who have localized prostate cancer. 22 Conversely, a high proportion of patients with non-metastatic prostate cancer and poor prognostic factors, treated with radical therapy alone, progress; at 5-year follow-up, 71-88% have prostatespecific antigen (PSA) progression. 23, 24 Over the past two decades, a number of randomized clinical trials have investigated the use of adjuvant hormonal therapy in patients with poor-prognosis nonmetastatic prostate cancer. However, despite positive survival results, adjuvant hormonal therapy is still viewed by clinicians as a palliative treatment option in this setting. The European Association of Urology and the American Society of Clinical Oncology treatment guidelines do not specifically categorize adjuvant hormonal therapy as being a potentially curative treatment option. 25, 26 The origin of the palliative label attached to luteinizing hormone-releasing hormone (LHRH) agonists stems from the historical use of androgen deprivation therapy among men with metastatic cancer. Although the antitumor effects of castration were revolutionary, the vast majority of men developed hormone refractory disease and died within 3 years of starting treatment. However, it is plausible that with minimal metastatic disease, hormone therapy could obliterate even hormone insensitive clones by paracrine mechanisms.
By applying our revised definition of long-term control and cure to the findings from randomized clinical trials investigating hormonal therapy, we have examined whether adjuvant hormonal therapies should be reclassified as treatments of curative intent in poor-prognosis non-metastatic prostate cancer.
Defining poor-prognosis non-metastatic prostate cancer. A range of definitions exist in the literature concerning what is meant by poor-prognosis non-metastatic prostate cancer. [27] [28] [29] [30] [31] [32] However, for the purposes of this review, we have only examined findings from randomized clinical studies that enrolled patients meeting a set of conservative and well-substantiated prognostic criteria (Table 1) . Patients with non-metastatic disease who meet the following criteria clearly have a poor prognosis: cN12, cM0 and either Gleason scoreX8; or PSA level X20 ng/ ml; or stage cT3/4; or adverse pathologic features, that is, pT3b/pT4 or dominant Gleason grade pattern 4. We acknowledge that in clinical practice these factors are never considered in isolation. However, for the purposes of this review, we believe these criteria to be appropriate for applying to the available clinical data.
Evidence from castration-based hormonal therapy trials with a follow-up duration greater than 5 years Clinical trials have shown that adjuvant therapy with LHRH agonists is effective in treating patients with prostate cancer. Specifically, goserelin is the most widely researched LHRH agonist, and is unique in having been studied as an adjuvant therapy in a number of randomized controlled studies with a follow-up of greater than 5 years and with survival as an endpoint. Long-term (10-15 years) Kaplan-Meier data from randomized clinical trials of goserelin provide an ideal opportunity to investigate if this agent provides longterm cancer control and cure for some patients when given adjuvant to standard care.
Indefinite treatment with goserelin adjuvant to radical prostatectomy or radiotherapy. To assess the efficacy of Treatment of poor prognosis, nonmetastatic prostate cancer N Fleshner et al goserelin when given adjuvant to radical prostatectomy, Messing and co-workers conducted a study (Eastern Cooperative Oncology Group (ECOG) 7887) on 98 men with clinically localized disease, who were found to have positive lymph nodes at surgery but no evidence of metastases. 33 Patients were randomized to receive either immediate hormonal therapy (n ¼ 47; 33 received goserelin, 13 underwent orchiectomy and one refused either treatment) or observation (n ¼ 51), with both strategies continuing until disease progression. After a median follow-up of 7.1 years, significantly fewer men in the immediate hormonal therapy group died compared with the observation group (14.9% versus 35.3%, respectively; P ¼ 0.02). The overall survival curves among men treated with adjuvant LHRH indicate that survival may be approaching the rate seen in the general population who do not have prostate cancer (Figure 2a) . Furthermore, the prostate cancer-specific survival curve shown in Figure 2b (Po0.01 between-group comparison) is flattening. Therefore, in this study, adjuvant hormonal therapy (including goserelin) may be providing sufficiently longterm control of disease to meet our definition of cure in a sizeable proportion of patients. The most recent analysis of data from this study (median follow-up 10 years) confirms that the trend in favor of adjuvant goserelin is continuing 34 (Messing, personal communication) .
ECOG 7887 was open only to patients with a specific type of prostate cancer that is seen infrequently today, particularly in the USA. This led to a slow rate of accrual, a limited number of patients enrolled and early closure of this study. Consequently, on the basis of this evidence alone, it is not possible to conclude that adjuvant goserelin should be classified as a treatment of curative intent. However, other larger studies of adjuvant goserelin have been conducted, which also show favorable findings and support the ECOG 7887 data: the Radiation Therapy Oncology Group (RTOG) Protocol 85-31 study, the European Organisation for Research and Treatment of Cancer (EORTC) 22863 trial and the RTOG 92-02 study.
The first of these studies, RTOG 85-31, investigated the benefits of goserelin adjuvant to radiotherapy in patients with locally advanced prostate cancer with a high metastatic risk (regional lymph node involvement or extensive capsular penetration, that is, cT3). 35 A total of 945 patients were available for analysis following randomization to either pelvic radiotherapy alone (n ¼ 468) or radiation plus adjuvant goserelin (n ¼ 477), with the hormonal therapy continued until disease progression. At the time of analysis (April 2005), the median follow-up was 7.6 years for all patients and 11 years for surviving patients. The 10-year estimates of absolute mortality (51% versus 61%; P ¼ 0.002) and disease-specific mortality (16% versus 22%; P ¼ 0.0052; see Figure 3 ) were significantly improved in the goserelin plus radiotherapy arm relative to radiotherapy alone. As mortality from prostate cancer in the adjuvant goserelin group has become negligible, it is likely that, as in the ECOG 7887 study, a subset of this population meets our revised definition of cancer control and cure, as some men who were destined to die without adjuvant therapy have achieved long-term cancer control (Figure 3a and b) .
Three years' treatment with goserelin adjuvant to radiotherapy. Further evidence for the efficacy of goserelin adjuvant to radiotherapy in patients with locally advanced prostate cancer is provided by findings from the EORTC 22863 trial. 36, 37 In this trial, 415 men with prostate cancer and a poor prognosis (T1-4, Nx, M0) were randomized to receive either radiotherapy with immediate goserelin for 3 years or until disease progression (n ¼ 207), or radiotherapy alone until disease progression (n ¼ 208). As with the RTOG 85-31 study, this trial showed that the survival outcome with radiotherapy was significantly improved by the inclusion of adjuvant goserelin therapy (hazard ratio 0.51; median follow-up of 5.5 years). Overall survival (Figure 4a ) differed significantly between groups, and at 5 years was 78% in the adjuvant goserelin group and 62% in the radiotherapy-alone group (P ¼ 0.0002). In terms of 5-year disease-free survival (assessed biochemically by measuring serum PSA concentration; progression was defined as PSA 41.5 mg/l, with increases in PSA at two consecutive measurements), adjuvant goserelin therapy was also better than radiotherapy given alone: 76 versus 45%, respectively (Po0.0001). Figure 4b illustrates the Kaplan-Meier estimates of biochemical disease-free survival in the two study populations. The disease-free survival curve for the adjuvant goserelin group is Treatment of poor prognosis, nonmetastatic prostate cancer N Fleshner et al beginning to indicate long-term control of disease, which would meet our revised definition of cure (that is, flattening out and running parallel to but separated from the radiotherapy alone group). At present, the data do not reach 10-15 years, as used for our definition. However, these data support the conclusions drawn from the ECOG 7887 and RTOG 85-31 studies, and we feel that adjuvant goserelin may achieve sufficiently long-term control of disease to be considered curative in a considerable proportion of these patients. This particular trial is interesting because patients have been treated with a 3-year regimen rather than indefinite androgen suppression. This distinction is important as, for some, the concept of cure refers to a person who is no longer on therapy. Although some men do not recover androgen synthesis following 3 years of LHRH therapy, 38, 39 the concept of cure is enforced by normal level of serum androgens. These data also raise the question of whether or not it is appropriate to stop androgen suppression at a point in time when a patient is free of disease, similar to tamoxifen withdrawal following the therapy of certain stages of breast cancer. Currently there are insufficient data to answer this question and further investigation through randomized clinical trials is needed.
Goserelin adjuvant to radiotherapy plus neoadjuvant hormonal therapy. In contrast to the studies discussed above, the RTOG 92-02 study evaluated adjuvant goserelin in patients (n ¼ 1554; stage T2c-4 disease) who had already received neoadjuvant hormonal therapy (goserelin plus flutamide for 2 months before and 2 months during radiotherapy). 40 The median follow-up period of this study (5.8 years) is similar to the EORTC 22863 trial. Regarding clinical progression-free survival, the study found that 2 years of adjuvant goserelin treatment provides significant advantages versus neoadjuvant hormonal therapy plus radiotherapy (Po0.0001). No statistically significant treatment difference in overall survival was seen. However, in patients with poor prognosis (Gleason scoreX8), adjuvant goserelin demonstrated a significant overall survival advantage (P ¼ 0.044): the respective estimated 5-year overall survival rates were 81 versus 71% for adjuvant goserelin versus no adjuvant treatment. The length of follow-up in this study is too short to ascertain whether adjuvant goserelin is achieving cancer control and a cure (according to our revised definition), which emphasizes that the concept of cure should only be discussed in the context of data from survival curves spanning 10-15 years. Nevertheless, the findings do support the effectiveness of adjuvant goserelin in men with non-metastatic prostate cancer and poor prognosis.
Evidence from trials with adjuvant castration: summary. This section has reviewed data from several randomized Treatment of poor prognosis, nonmetastatic prostate cancer N Fleshner et al controlled studies in patients with prostate cancer, which provide evidence that adjuvant castration including goserelin and orchiectomy, prevents disease relapse. Although there are inherent complexities associated with comparing across therapy areas, it is worth noting that generally similar long-term results with tamoxifen in women with breast cancer led to this agent becoming classed as a treatment of curative intent when given adjuvant to surgery. The investigations reviewed here have used different protocols with respect to duration of treatment, and this is an important factor when considering outcomes of hormonal therapy; therefore, more data are needed to determine which option is most successful. However, it is clear from the data reviewed for goserelin that, once Kaplan-Meier survival curves flatten, patients have a life expectancy equivalent to men without prostate cancer of a comparable age in the general population. This suggests that adjuvant goserelin therapy should be considered a curative treatment in a substantial proportion of patients with poor-prognosis nonmetastatic prostate cancer.
Importance of patients' quality of life in the decision-making process
From our clinical experience, it is of increasing importance to patients that they receive effective, welltolerated treatments that have minimal impact on quality of life. This is in part due to the fact that many patients are now being diagnosed at a younger age, with earlierstage disease, are living longer than before and consequently, are likely to require more long-term treatment. Thus, when making therapeutic decisions, the expected benefit of treatment should be discussed with the patient in conjunction with the treatment's impact on quality of life. In prostate cancer, chemotherapeutic agents are reserved for use in the hormone-resistant metastatic disease setting, as hormonal therapies are more effective in early disease. The recent success of taxotere-based treatment will result in trials of these agents in the adjuvant setting. The side effects of chemotherapy drugs on healthy dividing cells include myelosuppression, myalgia, gastrointestinal toxicity, fever and alopecia. 41 As these side effects can be severe, the use of chemotherapeutics agents may be reserved for treatment of the later stages of prostate cancer. Unlike chemotherapy agents, castration-based therapies have more discriminatory effects. The physical side effects of castration are related to the pharmacology of the treatment (that is, fatigue, decreased libido, sexual dysfunction, hot flashes, loss of bone mineral density and anemia). 42 Although the toxicity of castration is not as severe as cytotoxic chemotherapy, increasing recognition of these adverse effects must be acknowledged and balanced against the benefits they provide. There have been relatively few investigations of quality of life for patients receiving castration-based therapies, however, increasing recognition of the impact that side effects have on patients' lifestyles has resulted in interest in time-limited treatment strategies. Overall, it is essential to balance the benefit of prolonging survival against the impact of treatment on quality of life. When the impact on quality of life is substantial, many patients might choose improved quality of life over prolonged survival.
Conclusions
Findings from long-term, randomized controlled clinical trials indicate that adjuvant goserelin therapy should be considered curative, because long-term disease control is achieved in a sizeable proportion of men who have non-metastatic prostate cancer and a poor prognosis. Consistently, across a number of trials, the Kaplan-Meier survival curves for populations treated with adjuvant goserelin became flat after long-term follow-up, indicating insignificant further mortality from prostate cancer. Furthermore, overall survival is not declining at a rate that suggests significant treatment-induced mortality. Therefore, patients have a risk of mortality similar to the general population without prostate cancer: indeed, their risk of dying from prostate cancer may be less than the risk for the general population. From the evidence we have presented in this review, we believe that the traditional view of androgen deprivation as palliative is no longer accurate. We propose that adjuvant goserelin should be reclassified as a treatment of curative intent for patients with non-metastatic prostate cancer and poor prognostic factors, given that it can control prostate cancer for a long period of time, allowing patients to outlive their disease.
